歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > Proteases/Proteasome > MMP13-IN-3

瀏覽歷史

S89349

MMP13-IN-3

源葉(MedMol) 98%
  • 英文名:
  • 4-((5-(2-(Ethoxycarbonyl)-1H-indol-5-yl)-1-methyl-1H-pyrazole-3-carboxamido)methyl)benzoic acid
  • 別名:
  • BI-4394; BI4394; BI 4394
  • CAS號(hào):
  • 1222173-37-6
  • 分子式:
  • C24H22N4O5
  • 分子量:
  • 446.46
  • 核磁/質(zhì)譜:
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S89349-5mg 98% ¥1275.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
源葉(MedMol) S89349-10mg 98% ¥2040.00元 5 - - - EA 加入購(gòu)物車
源葉(MedMol) S89349-25mg 98% ¥4080.00元 6 - - - EA 加入購(gòu)物車
源葉(MedMol) S89349-100mg 98% ¥9800.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 產(chǎn)品描述: BI-4394 (MMP13-IN-3) 是一種有效的選擇性口服活性 MMP-13 抑制劑(IC50=1 nM)的潛在治療骨關(guān)節(jié)炎.BI-4394 比其他 MMP 具有 >1000 選擇性
  • 靶點(diǎn): MMP-13:1 nM (IC50);MMP-14:8.3 μM (IC50);MMP-9:8.9 μM (IC50);MMP-10:16 μM (IC50);MMP-2:18 μM (IC50);MMP
  • 體外研究:
    MMP13-IN-3 (Compound 15) is potent in a full-length MMP-13 collagen degradation assay (11 nM) and is able to inhibit degradation of bovine nasal cartilage with an IC50 of 31 nM. MMP13-IN-3 inhibits MMP-2, MMP-9, MMP-10 and MMP-14 with IC50s of 18, 8.9, 16 and 8.3 μM, respectively.
  • 體內(nèi)研究:
    When dosed orally at 10 mg/kg or i.v. 1 mg/kg, MMP13-IN-3 (Compound 15) reaches micromolar plasma levels (AUC=1109±64 nM h/mL), displays modest clearance (CL=34 mL/min/kg), and shows acceptable bioavailability (39%). The Vss is quite low at 0.26 mL/mi/kg rat pharmacokinetic profile. MMP13-IN-3 has short terminal elimination half-life (t1/2=0.47 h for rat (1 mg/kg, i.v.) and rat (10 mg/kg, orally), respectively). Animal Model:Srapgue Dally Rats Dosage:10 mg/kg (oral gavage); 1 mg/kg (i.v.) Administration:Dosed orally (10 mg/kg); i.v. (1 mg/kg)(Pharmacokinetic Analysis)Result:T1/2=0.47 h for rat (1 mg/kg, i.v.) and rat (10 mg/kg, orally) , respectively.
  • 參考文獻(xiàn):
    1. Taylor SJ, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87.
    2. Ruminski PG, et al. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. J Med Chem. 2016 Jan 14;59(1):313-27.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.24 ml 11.199 ml 22.398 ml
    5 mM 0.448 ml 2.24 ml 4.48 ml
    10 mM 0.224 ml 1.12 ml 2.24 ml
    50 mM 0.045 ml 0.224 ml 0.448 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
  • 產(chǎn)品描述: BI-4394 (MMP13-IN-3) 是一種有效的選擇性口服活性 MMP-13 抑制劑(IC50=1 nM)的潛在治療骨關(guān)節(jié)炎.BI-4394 比其他 MMP 具有 >1000 選擇性
  • 靶點(diǎn): MMP-13:1 nM (IC50);MMP-14:8.3 μM (IC50);MMP-9:8.9 μM (IC50);MMP-10:16 μM (IC50);MMP-2:18 μM (IC50);MMP
  • 體外研究:
    MMP13-IN-3 (Compound 15) is potent in a full-length MMP-13 collagen degradation assay (11 nM) and is able to inhibit degradation of bovine nasal cartilage with an IC50 of 31 nM. MMP13-IN-3 inhibits MMP-2, MMP-9, MMP-10 and MMP-14 with IC50s of 18, 8.9, 16 and 8.3 μM, respectively.
  • 體內(nèi)研究:
    When dosed orally at 10 mg/kg or i.v. 1 mg/kg, MMP13-IN-3 (Compound 15) reaches micromolar plasma levels (AUC=1109±64 nM h/mL), displays modest clearance (CL=34 mL/min/kg), and shows acceptable bioavailability (39%). The Vss is quite low at 0.26 mL/mi/kg rat pharmacokinetic profile. MMP13-IN-3 has short terminal elimination half-life (t1/2=0.47 h for rat (1 mg/kg, i.v.) and rat (10 mg/kg, orally), respectively). Animal Model:Srapgue Dally Rats Dosage:10 mg/kg (oral gavage); 1 mg/kg (i.v.) Administration:Dosed orally (10 mg/kg); i.v. (1 mg/kg)(Pharmacokinetic Analysis)Result:T1/2=0.47 h for rat (1 mg/kg, i.v.) and rat (10 mg/kg, orally) , respectively.
  • 參考文獻(xiàn):
    1. Taylor SJ, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87.
    2. Ruminski PG, et al. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. J Med Chem. 2016 Jan 14;59(1):313-27.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.24 ml 11.199 ml 22.398 ml
    5 mM 0.448 ml 2.24 ml 4.48 ml
    10 mM 0.224 ml 1.12 ml 2.24 ml
    50 mM 0.045 ml 0.224 ml 0.448 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩